PURPOSE: Physician reported symptomatic late rectal injury occurs in about 5% to 25% of patients treated with radiation therapy for prostate cancer, depending on the treatment technique. Patients, however, report clinically meaningful declines in bowel/rectal function regardless of the technique used. Lovastatin has been shown to protect mice from late radiation injury. This study was designed to determine if lovastatin might reduce the incidence of late rectal injury in patients receiving radiation therapy for prostate cancer. MATERIALS AND METHODS: Patients with adenocarcinoma of the prostate receiving radiotherapy with curative intent were eligible. A portion of the rectum had to receive at least 60 Gy. Gastrointestinal functioning was assessed using both physician-reported and patient-reported instruments at baseline and at prescribed intervals during and after treatment. Lovastatin (20 to 80 mg/d) was started on day 1 of radiation and continued for 12 months. Patients were followed for an additional 12 months. The primary endpoint was physician-reported rectal toxicity ≥grade 2 during the first 2 years after treatment. RESULTS: A total of 20/53 (38%) patients developed grade 2 or higher toxicity during the 2-year follow-up period. Seventeen patients had 1 or more unresolved gastrointestinal symptom at the end of 2 years, 3 (6%) of which were grade 2 and none were of higher grade. CONCLUSIONS: The primary endpoint of the study was not met. Lovastatin, as administered in this trial, did not reduce the incidence of grade 2 or higher rectal toxicity compared with historical controls.
PURPOSE: Physician reported symptomatic late rectal injury occurs in about 5% to 25% of patients treated with radiation therapy for prostate cancer, depending on the treatment technique. Patients, however, report clinically meaningful declines in bowel/rectal function regardless of the technique used. Lovastatin has been shown to protect mice from late radiation injury. This study was designed to determine if lovastatin might reduce the incidence of late rectal injury in patients receiving radiation therapy for prostate cancer. MATERIALS AND METHODS:Patients with adenocarcinoma of the prostate receiving radiotherapy with curative intent were eligible. A portion of the rectum had to receive at least 60 Gy. Gastrointestinal functioning was assessed using both physician-reported and patient-reported instruments at baseline and at prescribed intervals during and after treatment. Lovastatin (20 to 80 mg/d) was started on day 1 of radiation and continued for 12 months. Patients were followed for an additional 12 months. The primary endpoint was physician-reported rectal toxicity ≥grade 2 during the first 2 years after treatment. RESULTS: A total of 20/53 (38%) patients developed grade 2 or higher toxicity during the 2-year follow-up period. Seventeen patients had 1 or more unresolved gastrointestinal symptom at the end of 2 years, 3 (6%) of which were grade 2 and none were of higher grade. CONCLUSIONS: The primary endpoint of the study was not met. Lovastatin, as administered in this trial, did not reduce the incidence of grade 2 or higher rectal toxicity compared with historical controls.
Authors: Lars Budäus; Michel Bolla; Alberto Bossi; Cesare Cozzarini; Juanita Crook; Anders Widmark; Thomas Wiegel Journal: Eur Urol Date: 2011-10-06 Impact factor: 20.096
Authors: Susan L Tucker; Lei Dong; Jeff M Michalski; Walter R Bosch; Kathryn Winter; James D Cox; James A Purdy; Radhe Mohan Journal: Int J Radiat Oncol Biol Phys Date: 2012-02-17 Impact factor: 7.038
Authors: Nasiruddin Mohammed; Larry Kestin; Mihai Ghilezan; Daniel Krauss; Frank Vicini; Donald Brabbins; Gary Gustafson; Hong Ye; Alavaro Martinez Journal: Int J Radiat Oncol Biol Phys Date: 2010-12-16 Impact factor: 7.038
Authors: Marie Catherine Vozenin-Brotons; Fabien Milliat; Jean Christophe Sabourin; Anne Charlotte de Gouville; Agnès François; Philipe Lasser; Philipe Morice; Christine Haie-Meder; Antoine Lusinchi; Sami Antoun; Jean Bourhis; Denis Mathé; Theo Girinsky; Jocelyne Aigueperse Journal: Int J Radiat Oncol Biol Phys Date: 2003-06-01 Impact factor: 7.038
Authors: Christian Ostrau; Johannes Hülsenbeck; Melanie Herzog; Arno Schad; Michael Torzewski; Karl J Lackner; Gerhard Fritz Journal: Radiother Oncol Date: 2009-07-15 Impact factor: 6.280
Authors: Deborah E Citrin; Pataje G S Prasanna; Amanda J Walker; Michael L Freeman; Iris Eke; Mary Helen Barcellos-Hoff; Molykutty J Arankalayil; Eric P Cohen; Ruth C Wilkins; Mansoor M Ahmed; Mitchell S Anscher; Benjamin Movsas; Jeffrey C Buchsbaum; Marc S Mendonca; Thomas A Wynn; C Norman Coleman Journal: Radiat Res Date: 2017-05-10 Impact factor: 2.841
Authors: Michael B Jameson; Kirsten Gormly; David Espinoza; Wendy Hague; Gholamreza Asghari; Grahame Mark Jeffery; Timothy Jay Price; Christos Stelios Karapetis; Michael Arendse; James Armstrong; John Childs; Frank A Frizelle; Sam Ngan; Andrew Stevenson; Martinus Oostendorp; Stephen P Ackland Journal: BMC Cancer Date: 2019-12-17 Impact factor: 4.430